Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 7Melanoma 5Neoplasms 4Thyroid Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Uveal Melanoma 2Thyroid Cancer, Papillary 2Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Diseases 1Thymoma 1Solid Tumours 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroma, Acoustic 1Neurofibrosarcoma 1Neurofibromatosis 2 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × AZD 6244 × Clear all
NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡